help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montrella-Waybill, M.
Right arrow Articles by Watlington, C. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montrella-Waybill, M.
Right arrow Articles by Watlington, C. O.

Journal of Clinical Endocrinology & Metabolism, Vol 72, 1060-1066, Copyright © 1991 by Endocrine Society


ARTICLES

Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor

M Montrella-Waybill, JN Clore, AC Schoolwerth and CO Watlington
Department of Medicine, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0145.

We have previously shown that high dose cortisol (F; 240 mg/day)- induced Na+ retention and systolic blood pressure (BP) increases are not inhibited by the glucocorticoid (type II) receptor antagonist RU486. Adequacy of type II receptor blockade with RU486 was clearly demonstrated, indicating that the Na+ retention was not mediated through the glucocorticoid receptor. Spironolactone (Sp: 400 mg/day), in a preliminary assessment, also did not inhibit F-induced Na+ retention. The purpose of this study was to determine whether the Na+ retention produced by F administration is mediated by the type I receptor by comparing the effects of F to a potent type I agonist [9 alpha-fludrohydrocortisone (9 alpha FF)] with and without Sp administration. The effects of the two agonists and Sp on urinary K excretion and BP were also compared. Normal male volunteers, on a constant daily diet for 10 days, received either F (240 mg/day) or 9 alpha FF (3.0 mg/day) with or without Sp (400 mg/day) for the last 5 days. The mean cumulative reductions in Na+ excretion during the 5 days compared to baseline values before hormone administration were 255 +/- 38 and 494 +/- 81 mmol/5 days for F (n = 9) and 9 alpha FF (n = 5), respectively (P = 0.01). Sp (n = 5) completely inhibited 9 alpha FF- induced Na+ retention (494 +/- 81 vs. -37 +/- 130 mmol/5 days; P less than 0.01), but had no effect (n = 5) on F-induced Na+ retention (255 +/- 38 vs. 193 +/- 50 mmol/5 days; P = NS). After the expected first day kaliuresis, the effects of both steroids on net cumulative urinary K+ excretion were minimal. Systolic BP was increased by F, but not 9 alpha FF, and Sp did not inhibit this increase. A 2-fold greater Sp- inhibitable Na(+)-retaining effect of the mineralocorticoid demonstrates that the failure of Sp to block F-induced Na+ retention is not due to inadequate type I receptor blockade. Based on these findings and earlier studies, we conclude that high dose (stress level) F- induced Na+ retention and systolic BP increase are not mediated by either the mineralo- or glucocorticoid receptor in normal man.


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
J. E. Goodwin, J. Zhang, and D. S. Geller
A Critical Role for Vascular Smooth Muscle in Acute Glucocorticoid-Induced Hypertension
J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1291 - 1299.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
V. E. Mick, O. A. Itani, R. W. Loftus, R. F. Husted, T. J. Schmidt, and C. P. Thomas
The {{alpha}}-Subunit of the Epithelial Sodium Channel Is an Aldosterone-Induced Transcript in Mammalian Collecting Ducts, and This Transcriptional Response Is Mediated via Distinct cis-Elements in the 5'-Flanking Region of the Gene
Mol. Endocrinol., April 1, 2001; 15(4): 575 - 588.
[Abstract] [Full Text]


Home page
HypertensionHome page
J. A. Whitworth, G. J. Mangos, and J. J. Kelly
Cushing, Cortisol, and Cardiovascular Disease
Hypertension, November 1, 2000; 36(5): 912 - 916.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Shibata, H. Suzuki, T. Maruyama, and T. Saruta
Gene Expression of Angiotensin II Receptor in Blood Cells of Cushing's Syndrome
Hypertension, December 1, 1995; 26(6): 1003 - 1010.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society